Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

246
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
246
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

84
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
84
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

106
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
106
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

317
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
317
Methods of Documentation VI: Case Management Model01:15

Methods of Documentation VI: Case Management Model

731
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
731
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

183
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
183

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcomes and prognosis of mixed cryoglobulinaemia: a European multicentre study of 1294 patients.

Rheumatology (Oxford, England)·2026
Same author

Altered global longitudinal strain is a common finding in liver transplant recipients with mild cardiometabolic burden.

Internal and emergency medicine·2026
Same author

Brain tumor susceptibility: From genetic predisposition syndromes to extended characterization of genomic determinants.

Critical reviews in oncology/hematology·2026
Same author

Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.

The New England journal of medicine·2026
Same author

Glioblastoma and PARP inhibitors: the importance of patient selection to maximize therapeutic benefits. A critical review.

Frontiers in oncology·2026
Same author

144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial.

Journal of hepatology·2026

Related Experiment Video

Updated: Nov 25, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.7K

Hepatitis C: clinical management and debated issues.

Stefano Gitto1, Carmela Cursaro2, Alessandra Bartoli2

  • 1Unit of Internal Medicine and Liver, University Hospital Careggi, Florence, Italy.

Minerva Medica
|December 15, 2020
PubMed
Summary

Direct-acting antivirals offer a safe and effective cure for Hepatitis C virus (HCV) infection, significantly reducing liver transplants. However, challenges remain in patient care delivery and understanding long-term effects for global HCV eradication.

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.5K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.2K

Related Experiment Videos

Last Updated: Nov 25, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.7K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.5K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.2K

Area of Science:

  • Hepatology
  • Virology
  • Public Health

Background:

  • Hepatitis C virus (HCV) affects 71 million globally, necessitating effective treatments.
  • Direct-acting antivirals (DAAs) represent a breakthrough in HCV therapy, targeting viral proteins essential for replication.
  • DAAs demonstrate high sustained virological response rates and an excellent safety profile.

Purpose of the Study:

  • To review the clinical challenges in managing Hepatitis C virus patients treated with DAAs.
  • To discuss the debated effects of viral clearance on metabolic, cardiovascular, immunologic, and neoplastic aspects.
  • To identify barriers hindering Hepatitis C virus care delivery and global eradication efforts.

Main Methods:

  • Literature review of clinical management strategies for DAAs.
  • Analysis of studies on post-treatment outcomes and potential side effects of viral clearance.
  • Examination of factors impeding access to HCV treatment and care.

Main Results:

  • DAA therapy has led to a significant decrease in liver transplants for HCV-related cirrhosis and cancer.
  • Debated issues include the long-term metabolic, cardiovascular, immunologic, and neoplastic consequences of viral clearance.
  • Identifying and overcoming barriers to care are critical for achieving Hepatitis C virus elimination.

Conclusions:

  • DAAs have revolutionized HCV treatment, improving patient outcomes and reducing the need for liver transplantation.
  • Further research is needed to fully understand the multifaceted effects of viral clearance and address clinical management challenges.
  • Achieving the World Health Organization's goal of global Hepatitis C virus eradication by 2030 requires a concerted, multilevel effort to overcome existing barriers to care.